TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Rocket Pharmaceuticals ( (RCKT) ).
On September 29, 2025, Pedro Granadillo resigned from the Board of Directors of Rocket Pharmaceuticals, effective September 30, 2025. His resignation was not due to any disagreements with the company’s operations, policies, or practices.
The most recent analyst rating on (RCKT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.
Spark’s Take on RCKT Stock
According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.
Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.
To see Spark’s full report on RCKT stock, click here.
More about Rocket Pharmaceuticals
Average Trading Volume: 3,692,847
Technical Sentiment Signal: Sell
Current Market Cap: $341M
Learn more about RCKT stock on TipRanks’ Stock Analysis page.